Werewolf Therapeutics, Inc.

NASDAQ:HOWL

Biotechnology

Healthcare
$1.03 +6.12%

+$0.06 today

Market cap
$50.06M
Beta
0.29
P/E (TTM)
-1.4
EPS (TTM)
-$0.71
52W Low $0.27High $1.83

Volume 1.85M

Average 5.09M

HOWL Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Werewolf Therapeutics, Inc.NASDAQ: HOWL

Operating Income · Q2 FY2026 · quarter ended Jun 2026

Operating income turns positive

Q2 FY2026 operating income was $8.54M, compared with -$17.54M a year earlier. Trailing-twelve-month operating income was -$25.57M.

Context

  • Operating income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether operating income reaches the consensus estimate from 2 analysts of -$37.3M (+38.5%) for the fiscal year ending Dec 2026, a step up from the +17.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$8.54M+195.2% QoQ
Last fiscal yearDec 2025
-$60.68M+17.6% YoY
LTMJun 2026
-$25.57M+65.0% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+148.7%——
1 year+17.6%+38.5%+21.0 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(60.68M) USD
Year-over-year change
+17.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How HOWL compares with its peers on the latest reported figures

  • HOWL's LTM Jun 2026 operating income of -$25.57M is the 3rd highest of the 8 companies compared; the peer median is -$34.01M.
  • Its year-over-year change of +65.0% is the highest of 8, against a peer median of +10.1%.
  • Operating income amounts to 121.8% of revenue for HOWL, versus a peer median of 749.7%.
HOWL Competitors Peer median
Operating Income for HOWL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026-$17.19M +2.1%—749.7%
CUECue Biopharma, Inc.LTM Mar 2026-$19.58M +52.4%—59.8%
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026-$25.57M +65.0%—121.8%
OSTXOS Therapies IncorporatedLTM Mar 2026-$33.87M -202.9%——
SPRBSpruce Biosciences, Inc.LTM Mar 2026-$34.01M +41.4%——
INMBINmune Bio, Inc.LTM Mar 2026-$43.29M -4.3%——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$60.57M +20.8%—18182.8%
ACETAdicet Bio, Inc.LTM Mar 2026-$113.8M +10.1%——
Peer median (excluding HOWL) -$34.01M+10.1%—749.7%

Competitors are the stored peer set for HOWL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue016.4M19.94M1.89M0
Cost of Revenue02.51M1.76M1.81M1.63M
Gross Profit013.89M18.18M71K(1.63M)
Gross Margin—84.7%91.2%3.8%—
Research & Development35.27M53.76M41.78M56.43M44.83M
Selling, General & Admin14.82M21.5M18.67M19.05M15.85M
Operating Expenses50.09M69.95M58.68M73.67M59.04M
Depreciation & Amortization216K1.1M1.76M1.81M1.63M
EBITDA(49.77M)(52.71M)(32.47M)(64.05M)(53.91M)
EBITDA Margin—-321.4%-162.8%-3397.6%—
Operating Income(50.09M)(56.06M)(40.5M)(73.59M)(60.68M)
Operating Margin—-341.8%-203.1%-3904.2%—
Interest Income104K1.91M7.42M6.67M3.11M
Interest Expense003.14M4.66M5.27M
Other Income / Expenses104K2.25M3.14M3.08M(145K)
Income Before Tax(49.98M)(53.81M)(37.37M)(70.52M)(60.82M)
Pre-Tax Margin—-328.1%-187.4%-3740.8%—
Income Tax Expense00000
Net Income(49.98M)(53.81M)(37.37M)(70.52M)(60.82M)
Net Margin—-328.1%-187.4%-3740.8%—
EPS (Basic)(10.94)(1.86)(1.05)(1.63)(1.32)
EPS (Diluted)(10.94)(1.86)(1.05)(1.63)(1.33)
Weighted Avg Shares18.46M28.86M35.65M43.33M46.02M
Weighted Avg Shares (Diluted)18.46M28.86M35.65M43.86M46.81M

Werewolf Therapeutics, Inc.

NASDAQ:HOWL

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.